DOCSLIB.ORG

Immune Checkpoint Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immune Checkpoint Receptors T Cell NK Cell Tumor Cell Killing of cancer cells Recognition of cancer cells by T cells NK Cell Tumor Cell T Cell TRAIL TRAILR1/2 ICOSL ICOS NKp30a,b B7-H6/BAT3/BAG6 HHLA2 TMIGD2 NKG2C HLA-E HVEM LIGHT NKG2D MICA family MHC class I/II KIRS NKG2D RAET1/ULBP family CD137L CD137 KIRS MHC class I/II OX40L OX40 CD27 CD70 CD70 CD27 Activation CD226 CD122 GITRL GITR Immune Checkpoint Receptors CD226 CD155 CD155 CD226 Activation CD244 CD48 CD48 CD244 CD86 CD28 CD80 CD28 CD244 CD48 CD96 CD122 CD86 CTLA-4 TIGIT CD122 CD80 CTLA-4 CD96 CD155 CD80 PDL1 TIGIT CD155 PDL1 CD80 NKG2A HLA-E PDL1 PD1 Inhibition PDL2 PD1 HVEM CD272 HVEM CD160 MHC class I/II KIR L Inhibition MHC class I/II CD223 CD155 CD96 CD112 TIGIT CD112 CD112R CD200 CD200R Gal-9 TIM-3 Abnova Abnova Corporation 9F, No. 108, Jhouzih St., Neihu, Taipei 114, Taiwan Tel: + 886 2 8751 1888 Fax: + 886 2 6602 1218 www.abnova.com Catalog No. BAT3 Related Products Applications Reactivity H00007917-AP21 BAT3 (Human) Matched Antibody Pair EPair-Re Human H00007917-P01 BAT3 (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00007917-T01 BAT3 293T Cell Transient Overexpression Lysate(Denatured) WB H00007917-B01 BAT3 MaxPab mouse polyclonal antibody (B01) WB-Ce,IF,WB-Tr Human H00007917-M03A BAT3 monoclonal antibody (M03A), clone 2B9 ELISA Human H00007917-B01P BAT3 purified MaxPab mouse polyclonal antibody (B01P) WB-Ce,IF,WB-Tr Human Catalog No. BTLA Related Products Applications Reactivity H00151888-Q01 BTLA (Human) Recombinant Protein (Q01) AP,Array,ELISA,WB-Re H00151888-M02 BTLA monoclonal antibody (M02), clone 1B7 ELISA,WB-Re Human H00151888-R01 BTLA Pre-design Chimera RNAi RNAi Human Catalog No. CD27 Related Products Applications Reactivity KA4202 CD27 (Human) ELISA Kit Quant Human H00000939-AP21 CD27 (Human) Matched Antibody Pair EPair-Re Human H00000939-G01 CD27 (Human) Recombinant Protein AP,Func,Screening MAB4397 CD27 monoclonal antibody, clone LT27 (APC) Flow Cyt Human H00000939-B01P CD27 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD28 Related Products Applications Reactivity KA0172 CD28 (Human) ELISA Kit Quant Human H00000940-AP41 CD28 (Human) Matched Antibody Pair EPair-Re Human PAB31656 CD28 (phospho Y218) polyclonal antibody WB,ELISA Human,Mouse H00000940-T02 CD28 293T Cell Transient Overexpression Lysate(Denatured) WB H00000940-M01 CD28 monoclonal antibody (M01), clone 2C1 ELISA,WB-Re Human H00000940-R02 CD28 Pre-design Chimera RNAi RNAi Human H00000940-B01P CD28 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD48 Related Products Applications Reactivity KA4529 CD48 (Human) ELISA Kit Quant Human H00000962-P01 CD48 (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00000962-T03 CD48 293T Cell Transient Overexpression Lysate(Denatured) WB H00000962-B01 CD48 MaxPab mouse polyclonal antibody (B01) WB-Ti,WB-Tr Human H00000962-M01 CD48 monoclonal antibody (M01), clone 3B8-2C2 IHC-P,S-ELISA,ELISA,WB-Re Human H00000962-R01 CD48 Pre-design Chimera RNAi RNAi Human H00000962-B01P CD48 purified MaxPab mouse polyclonal antibody (B01P) WB-Ti,WB-Tr Human Catalog No. CD70 Related Products Applications Reactivity H00000970-PW1 CD70 (Human) IP-WB Antibody Pair IP-WB Human H00000970-AP42 CD70 (Human) Matched Antibody Pair EPair-Re Human H00000970-G01 CD70 (Human) Recombinant Protein AP,Func,Screening H00000970-T01 CD70 293T Cell Transient Overexpression Lysate(Denatured) WB H00000970-D01 CD70 MaxPab rabbit polyclonal antibody (D01) WB-Tr,IP Human MAB6921 CD70 monoclonal antibody, clone BU69 IP,IHC-Fr,Flow Cyt Human H00000970-B01P CD70 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD80 Related Products Applications Reactivity KA3687 CD80 (Human) ELISA Kit Quant Human H00000941-PW2 CD80 (Human) IP-WB Antibody Pair IP-WB Human H00000941-AP41 CD80 (Human) Matched Antibody Pair EPair-Re Human H00000941-P01 CD80 (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00000941-T01 CD80 293T Cell Transient Overexpression Lysate(Denatured) WB H00000941-M01 CD80 monoclonal antibody (M01), clone 1G1 S-ELISA,ELISA,PLA-Ce Human H00000941-R01 CD80 Pre-design Chimera RNAi RNAi Human H00000941-B01P CD80 purified MaxPab mouse polyclonal antibody (B01P) WB-Ce,WB-Tr Human Abnova Corporation 9F, No. 108, Jhouzih St., Neihu, Taipei 114, Taiwan Tel: + 886 2 8751 1888 Fax: + 886 2 6602 1218 www.abnova.com Catalog No. CD86 Related Products Applications Reactivity DI0082 CD86 & CD80 Protein Protein Interaction Antibody Pair PLA-Ce Human DI0136 CD86 & CTLA4 Protein Protein Interaction Antibody Pair PLA-Ce Human KA3847 CD86 (Human) ELISA Kit Quant Human H00000942-PW1 CD86 (Human) IP-WB Antibody Pair IP-WB Human H00000942-AP21 CD86 (Human) Matched Antibody Pair EPair-Re Human H00000942-Q01 CD86 (Human) Recombinant Protein (Q01) AP,Array,ELISA,WB-Re H00000942-T01 CD86 293T Cell Transient Overexpression Lysate(Denatured) WB H00000942-M01 CD86 monoclonal antibody (M01), clone 3D7 S-ELISA,ELISA,IP Human H00000942-R03 CD86 Pre-design Chimera RNAi RNAi Human H00000942-B01P CD86 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD96 Related Products Applications Reactivity H00010225-PW1 CD96 (Human) IP-WB Antibody Pair IP-WB Human H00010225-AP51 CD96 (Human) Matched Antibody Pair EPair-Tr Human H00010225-P01 CD96 (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00010225-T02 CD96 293T Cell Transient Overexpression Lysate(Denatured) WB H00010225-B01 CD96 MaxPab mouse polyclonal antibody (B01) WB-Tr Human H00010225-M01 CD96 monoclonal antibody (M01), clone 3H8 S-ELISA,ELISA,WB-Re Human H00010225-R02 CD96 Pre-design Chimera RNAi RNAi Human H00010225-B01P CD96 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD160 Related Products Applications Reactivity H00011126-PW2 CD160 (Human) IP-WB Antibody Pair IP-WB Human H00011126-P02 CD160 (Human) Recombinant Protein (P02) AP,Array,ELISA,WB-Re H00011126-T02 CD160 293T Cell Transient Overexpression Lysate(Denatured) WB H00011126-D01 CD160 MaxPab rabbit polyclonal antibody (D01) WB-Tr,IP Human H00011126-R02 CD160 Pre-design Chimera RNAi RNAi Human H00011126-B01P CD160 purified MaxPab mouse polyclonal antibody (B01P) WB-Ti,WB-Tr Human Catalog No. CD200 Related Products Applications Reactivity KA4220 CD200 (Human) ELISA Kit Quant Human H00004345-G01 CD200 (Human) Recombinant Protein AP,Func,Screening H00004345-T01 CD200 293T Cell Transient Overexpression Lysate(Denatured) WB MAB16609 CD200 monoclonal antibody, clone 6E8B11 ELISA,WB-Tr Human H00004345-R02 CD200 Pre-design Chimera RNAi RNAi Human H00004345-B01P CD200 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. CD226 Related Products Applications Reactivity KA2650 CD226 (Human) Cell-Based ELISA Kit Qual Human,Mouse KA4523 CD226 (Human) ELISA Kit Quant Human H00010666-Q01 CD226 (Human) Recombinant Protein (Q01) AP,Array,ELISA,WB-Re H00010666-M04 CD226 monoclonal antibody (M04), clone 4G8 S-ELISA,ELISA Human H00010666-R02 CD226 Pre-design Chimera RNAi RNAi Human Catalog No. CD244 Related Products Applications Reactivity KA3366 CD244 (Human) ELISA Kit Quant Human H00051744-G01 CD244 (Human) Recombinant Protein AP,Func,Screening PAB17803 CD244 (phospho Y266) polyclonal antibody IP,ELISA,WB-Ce Human H00051744-R02 CD244 Pre-design Chimera RNAi RNAi Human Catalog No. CD274 Related Products Applications Reactivity KA4987 CD274 (Human) ELISA Kit Quant Human H00029126-AP41 CD274 (Human) Matched Antibody Pair EPair-Re Human H00029126-Q01 CD274 (Human) Recombinant Protein (Q01) AP,Array,ELISA,WB-Re H00029126-M01 CD274 monoclonal antibody (M01), clone 3F4 ELISA,WB-Re Human H00029126-R01 CD274 Pre-design Chimera RNAi RNAi Human H00029126-B01P CD274 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Abnova Corporation 9F, No. 108, Jhouzih St., Neihu, Taipei 114, Taiwan Tel: + 886 2 8751 1888 Fax: + 886 2 6602 1218 www.abnova.com Catalog No. CD274 Related Products Applications Reactivity FG0160 CD274(PD-L1)/CEN9q FISH Probe Hybridize FG0224 CD274(PD-L1)/CEN9q FISH Probe FISH-Ce FG0226 CD274(PD-L1)-PDCD1LG2(CD273)/CEN9q FISH Probe FISH-Ce FG0191 CD274/CD273/CEN9q FISH Probe FISH-Ce FG0167 CD274/CEN9q FISH Probe FISH-Ce Catalog No. CTLA4 Related Products Applications Reactivity DI0138 STAT5A & CTLA4 Protein Protein Interaction Antibody Pair PLA-Ce Human DI0139 STAT5B & CTLA4 Protein Protein Interaction Antibody Pair PLA-Ce Human DI0137 FYN & CTLA4 Protein Protein Interaction Antibody Pair PLA-Ce Human KA0165 CTLA4 (Human) ELISA Kit Quant Human H00001493-AP41 CTLA4 (Human) Matched Antibody Pair EPair-Re Human H00001493-H01 CTLA4 (Human) Recombinant Protein WB,ELISA,SDS-PAGE,PI H00001493-M08 CTLA4 monoclonal antibody (M08), clone 1F4 S-ELISA,ELISA,WB-Re,PLA-Ce Human H00001493-R01 CTLA4 Pre-design Chimera RNAi RNAi Human Catalog No. HHLA2 Related Products Applications Reactivity H00011148-P01 HHLA2 (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00011148-T01 HHLA2 293T Cell Transient Overexpression Lysate(Denatured) WB H00011148-B01P HHLA2 purified MaxPab mouse polyclonal antibody (B01P) WB-Tr Human Catalog No. HLA-E Related Products Applications Reactivity MAB3854 HLA Class I monoclonal antibody, clone MEM-123 IP,ELISA,Flow Cyt Bovine,Human H00003133-PW2 HLA-E (Human) IP-WB Antibody Pair IP-WB Human H00003133-P01 HLA-E (Human) Recombinant Protein (P01) AP,Array,ELISA,WB-Re H00003133-P02 HLA-E (Human) Recombinant Protein (P02) AP,Array,ELISA,WB-Re H00003133-T01 HLA-E 293T Cell Transient Overexpression Lysate(Denatured) WB H00003133-T02 HLA-E 293T Cell Transient Overexpression
Load more

Recommended publications
  • Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation
    Review Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation Chiara Rizzo 1, Giulia Grasso 1, Giulia Maria Destro Castaniti 1, Francesco Ciccia 2 and Giuliana Guggino 1,* 1 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology Section, University of Palermo, Piazza delle Cliniche 2, 90110 Palermo, Italy; [email protected] (C.R.); [email protected] (G.G.); [email protected] (G.M.D.C.) 2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-091-6552260 Received: 30 April 2020; Accepted: 29 May 2020; Published: 3 June 2020 Abstract: Primary Sjogren Syndrome (pSS) is a complex, multifactorial rheumatic disease that mainly targets salivary and lacrimal glands, inducing epithelitis. The cause behind the autoimmunity outbreak in pSS is still elusive; however, it seems related to an aberrant reaction to exogenous triggers such as viruses, combined with individual genetic pre-disposition. For a long time, autoantibodies were considered as the hallmarks of this disease; however, more recently the complex interplay between innate and adaptive immunity as well as the consequent inflammatory process have emerged as the main mechanisms of pSS pathogenesis. The present review will focus on innate cells and on the principal mechanisms of inflammation connected. In the first part, an overview of innate cells involved in pSS pathogenesis is provided, stressing in particular the role of Innate Lymphoid Cells (ILCs). Subsequently we have highlighted the main inflammatory pathways, including intra- and extra-cellular players.
    [Show full text]
  • Recombinant Human NCR3/Nkp300 Protein
    Leader in Biomolecular Solutions for Life Science Recombinant Human NCR3/NKp300 Protein Catalog No.: RP00179 Recombinant Sequence Information Background Species Gene ID Swiss Prot Natural Cytotoxicity Triggering Receptor 3, NCR3, also known as NKp30, or CD337, Human 259197 O14931 is a natural cytotoxicity receptor. NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells Tags found in peripheral blood and spleen. NKp30 is absent from the CD56bright, CD16- C-Fc & 6×His subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up-regulated in these cells upon IL-2 activation .NKp30 is a Synonyms member of the immunoglobulin superfamily and one of three existing natural 1C7;CD337;DAAP-90L16.3;LY117;MALS cytotoxicity-triggering receptors. NKp30 is a glycosylated protein and is thought to ;NCR3;NKp30 be selectively expressed in resting and activated natural killer cells. NKp30 is a stimulatory receptor on human NK cells implicated in tumor immunity, and is capable of promoting or terminating dendritic cell maturation. NCR3 may play a role in inflammatory and infectious diseases. Product Information Source Purification Basic Information HEK293 cells > 95% by SDS- PAGE. Description Recombinant Human NCR3/NKp300 Protein is produced by HEK293 cells Endotoxin expression system. The target protein is expressed with sequence (Leu19-Thr138) < 0.1 EU/μg of the protein by LAL of human NCR3/NKp300 (Accession #NP_001138938.1) fused with an Fc, 6×His tag method. at the C-terminus. Formulation Bio-Activity Lyophilized from a 0.22 μm filtered Measured by its binding ability in a functional ELISA.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Human NK Cells with the 2B4 Receptor Inhibits Self-Killing of the Association of MHC Class I Proteins
    The Association of MHC Class I Proteins with the 2B4 Receptor Inhibits Self-Killing of Human NK Cells This information is current as Gili Betser-Cohen, Saar Mizrahi, Moran Elboim, Osnat of September 27, 2021. Alsheich-Bartok and Ofer Mandelboim J Immunol 2010; 184:2761-2768; Prepublished online 17 February 2010; doi: 10.4049/jimmunol.0901572 http://www.jimmunol.org/content/184/6/2761 Downloaded from References This article cites 39 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/184/6/2761.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Association of MHC Class I Proteins with the 2B4 Receptor Inhibits Self-Killing of Human NK Cells Gili Betser-Cohen, Saar Mizrahi, Moran Elboim, Osnat Alsheich-Bartok, and Ofer Mandelboim The killing activity of NK cells is carried out by several activating NK receptors, which includes NKp46, NKp44, NKp30, NKp80, NKG2D, and 2B4.
    [Show full text]
  • Selectins in Cancer Immunity
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 Selectins in cancer immunity Borsig, Lubor Abstract: Selectins are vascular adhesion molecules that mediate physiological responses such as inflam- mation, immunity and hemostasis. During cancer progression, selectins promote various steps enabling the interactions between tumor cells and the blood constituents, including platelets, endothelial cells and leukocytes. Selectins are carbohydrate-binding molecules that bind to sialylated, fucosylated glycan structures. The increased selectin ligand expression on tumor cells correlates with enhanced metastasis and poor prognosis for cancer patients. While, many studies focused on the role of selectin as a mediator of tumor cell adhesion and extravasation during metastasis, there is evidence for selectins to activate signaling cascade that regulates immune responses within a tumor microenvironment. L-Selectin binding induces activation of leukocytes, which can be further modulated by selectin-mediated interactions with platelets and endothelial cells. Selectin ligand on leukocytes, PSGL-1, triggers intracellular signaling in leukocytes that are induced through platelet’s P-selectin or endothelial E-selectin binding. In this review, I summarize the evidence for selectin-induced immune modulation in cancer progression that represents a possible target for controlling tumor immunity. DOI: https://doi.org/10.1093/glycob/cwx105 Posted at the Zurich Open Repository and
    [Show full text]
  • Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
    Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples Qiang Liu Chinese Academy of Medical Sciences & Peking Union Medical College Yihang Qi ( [email protected] ) Chinese Academy of Medical Sciences and Peking Union Medical College https://orcid.org/0000-0001- 7589-0333 Jie Zhai Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyi Kong Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyu Wang Chinese Academy of Medical Sciences & Peking Union Medical College Yi Fang Chinese Academy of Medical Sciences & Peking Union Medical College Jing Wang Chinese Academy of Medical Sciences & Peking Union Medical College Research Keywords: Cancer immunotherapy, CD223, LAG3, Immune response, Inammatory activity Posted Date: June 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-36422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a large number of cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, is a protein Coding gene served as alternative inhibitory receptors to be targeted in the clinic. The impact of LAG3 on immune cell populations and co-regulation of immune response in breast cancer remained largely unknown. Methods To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from a total of 2994 breast cancer patients. Results We observed that LAG3 was closely correlated with major molecular and clinical characteristics, and was more likely to be enriched in higher malignant subtype, suggesting LAG3 was a potential biomarker of triple-negative breast cancer.
    [Show full text]
  • Associated B Cell Lymphoma and Nasopharyngeal Carcinoma
    Contribution of tumour cell signalling and the microenvironment to the pathogenesis of EBV- associated B cell lymphoma and nasopharyngeal carcinoma BY MAHA IBRAHIM A thesis submitted to The University of Birmingham For the degree of DOCTOR OF PHILOSOPHY Institute of Cancer and Genomic Sciences College of Medical and Dental Sciences University of Birmingham May 2018 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract In this thesis I have explored different components of the pathogenesis of several related EBV associated cancers. In the first part of the thesis I focus on the microenvironment of two of these cancers, nasopharyngeal carcinoma (NPC) and diffuse large B cell lymphoma (DLBCL). Our group has developed a therapeutic vaccine against EBV which has already been shown to be safe in patients with NPC. Therefore, in the first results chapter (chapter 3), I present a description of the phenotyping of expression of the immune microenvironment including immune checkpoint (ICP) genes and MHC class I and class II genes in NPC tissues. I showed for the first time in NPC tissue samples, two types of PD-L1 expressing tumours: diffuse and marginal.
    [Show full text]
  • 5.01.591 Immune Checkpoint Inhibitors
    MEDICAL POLICY – 5.01.591 Immune Checkpoint Inhibitors Effective Date: Sept. 1, 2021 RELATED POLICIES/GUIDELINES: Last Revised: Aug. 10, 2021 5.01.543 General Medical Necessity Criteria for Companion Diagnostics Related Replaces: N/A to Drug Approval 5.01.589 BRAF and MEK Inhibitors Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Chemotherapy, often called chemo, is cancer treatment that uses drugs. Radiation and surgery treat one area of cancer. But chemo usually travels through the bloodstream to treat the whole body. Treating the whole body is called a systemic treatment. Immunotherapy is a new type of cancer treatment that helps the body’s immune cells fight the cancer more effectively. Cancer cells sometimes “hide” from the body’s cells that are designed to search for cells that don’t belong, like cancer cells or bacteria. Immune checkpoint inhibitors are drugs that block the way that cancer cells do this and so help the immune cells find them so they can be stopped. It is one of the ways we can make the environment less friendly to the cancer and slow its growth. Current immunotherapy drugs are complex molecules that must be given through a vein (intravenous). In the future, some may be given by a shot (injection) the patient could inject without help. This policy gives information about immunotherapy drugs and the criteria for when they may be medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria.
    [Show full text]
  • CD48 Is Critically Involved in Allergic Eosinophilic Airway Inflammation
    CD48 Is Critically Involved in Allergic Eosinophilic Airway Inflammation Ariel Munitz,1 Ido Bachelet,1 Fred D. Finkelman,2 Marc E. Rothenberg,3 and Francesca Levi-Schaffer1,4 1Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 2Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; 3Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio; and 4David R. Bloom Center for Pharmacology, Hebrew University of Jerusalem, Jerusalem, Israel Rationale: Despite ongoing research, the molecular mechanisms con- trolling asthma are still elusive. CD48 is a glycosylphosphatidylinositol- AT A GLANCE COMMENTARY anchored protein involved in lymphocyte adhesion, activation, and costimulation. Although CD48 is widely expressed on hematopoi- Scientific Knowledge on the Subject etic cells and commonly studied in the context of natural killer and CD48 is an activation molecule able to facilitate various cytotoxic T cell functions, its role in helper T cell type 2 settings cellular activities. Its role in asthma is unknown. has not been examined. Objectives: To evaluate the expression and function of CD48, CD2, and 2B4 in a murine model of allergic eosinophilic airway inflammation. What This Study Adds to the Field Methods: Allergic eosinophilic airway inflammation was induced by CD48 is upregulated in experimental asthma. Anti-CD48– ovalbumin (OVA)–alum sensitization and intranasal inoculation of based therapies may be useful for asthma and perhaps OVA or, alternatively, by repeated intranasal inoculation of Aspergil- various allergic diseases. lus fumigatus antigen in wild-type, STAT (signal transducer and acti- vator of transcription)-6–deficient, and IL-4/IL-13–deficient BALB/c mice.
    [Show full text]
  • LAG-3: from Molecular Functions to Clinical Applications
    Open access Review J Immunother Cancer: first published as 10.1136/jitc-2020-001014 on 13 September 2020. Downloaded from LAG-3: from molecular functions to clinical applications Takumi Maruhashi , Daisuke Sugiura , Il- mi Okazaki , Taku Okazaki To cite: Maruhashi T, Sugiura D, ABSTRACT (PD-1) and cytotoxic T lymphocyte antigen Okazaki I, et al. LAG-3: from To prevent the destruction of tissues owing to excessive 4 (CTLA-4) significantly improved the molecular functions to clinical and/or inappropriate immune responses, immune outcomes of patients with diverse cancer applications. Journal for cells are under strict check by various regulatory ImmunoTherapy of Cancer types, revolutionizing cancer treatment. The mechanisms at multiple points. Inhibitory coreceptors, 2020;8:e001014. doi:10.1136/ success of these therapies verified that inhib- including programmed cell death 1 (PD-1) and cytotoxic jitc-2020-001014 itory coreceptors serve as critical checkpoints T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against for immune cells to not attack the tumor Accepted 29 July 2020 self- tissues and tumor cells. Immune checkpoint inhibitors cells as well as self-tissues. However, response that block PD-1 and CTLA-4 pathways significantly rates are typically lower and immune-related improved the outcomes of patients with diverse cancer adverse events (irAEs) are also observed in types and have revolutionized cancer treatment. However, patients administered with immune check- response rates to such therapies are rather limited, and point inhibitors. This is indicative of the immune-rela ted adverse events are also observed in a continued need to decipher the complex substantial patient population, leading to the urgent need biology of inhibitory coreceptors to increase for novel therapeutics with higher efficacy and lower response rates and prevent such unwanted toxicity.
    [Show full text]
  • An Ontogenetic Switch Drives the Positive and Negative Selection of B Cells
    An ontogenetic switch drives the positive and negative selection of B cells Xijin Xua, Mukta Deobagkar-Lelea, Katherine R. Bulla, Tanya L. Crockforda, Adam J. Meadb, Adam P. Cribbsc, David Simsc, Consuelo Anzilottia, and Richard J. Cornalla,1 aMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; bMedical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; and cMedical Research Council, Weatherall Institute of Molecular Medicine, Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom Edited by Michael Reth, University of Freiburg, Freiburg, Germany, and approved January 6, 2020 (received for review September 3, 2019) + Developing B cells can be positively or negatively selected by self- BM HSCs increased CD5 B-1a B cell development (15), while antigens, but the mechanisms that determine these outcomes are expression of let-7b in FL pro-B cells blocked the development of incompletely understood. Here, we show that a B cell intrinsic B-1 B cells (17). These findings support the notion of hard-wired switch between positive and negative selection during ontogeny differences during ontogeny, but possibly downstream of the HSC is determined by a change from Lin28b to let-7 gene expression. commitment stage. Ectopic expression of a Lin28b transgene in murine B cells restored Several lines of evidence also suggest that B-1 B cells can un- the positive selection of autoreactive B-1 B cells by self-antigen in dergo positive selection, which is linked to their B cell receptor adult bone marrow.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]